Opioid-Induced Hypogonadism (OPIAD)
Opioid-induced androgen deficiency, a large, under-recognized cause
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not a product; a recognized adverse effect of opioid therapy
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about opioid-induced hypogonadism (opiad) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Opioid-induced androgen deficiency (OPIAD) is suppression of testosterone caused by chronic opioid use. Opioids inhibit hypothalamic GnRH, lowering LH and FSH and therefore testosterone, a secondary hypogonadism that can also involve a direct testicular effect and opioid-driven prolactin rise. Reported prevalence varies widely (roughly 19 to 86 percent depending on diagnostic criteria), with most studies above 50 percent, making it one of the most common and most overlooked drug causes of low testosterone. It is dose-dependent and can develop quickly.
The hidden hormonal cost of long-term opioids.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Opioids act on hypothalamic opioid receptors to inhibit GnRH synthesis and pulsatile release, dropping LH and FSH and hence testosterone. A contributing route is opioid-induced hyperprolactinemia, which further suppresses GnRH. Some evidence also points to a direct inhibitory effect on testicular steroidogenesis. The effect is dose-dependent: higher morphine-equivalent daily doses raise the likelihood and degree of suppression.
Why it is everywhere and still missed
OPIAD is massive in scale yet routinely undiagnosed because its symptoms, fatigue, low libido, depressed mood, sexual dysfunction, get attributed to chronic pain or its psychology rather than to the opioid itself. The most reliable fix is reducing or stopping the opioid where clinically feasible, which can allow recovery, rather than simply layering testosterone on top.
Safety in detail
OPIAD arises from a prescribed (or non-prescribed) medication with its own dependence and overdose risks. Opioid dose changes must be managed by the prescribing clinician; abrupt cessation carries its own dangers. Adding testosterone without addressing the opioid does not treat the cause and still requires medical oversight.
What it does to fertility
By suppressing LH and FSH, chronic opioids can impair spermatogenesis as well as testosterone, reducing fertility. Because the suppression is largely functional, lowering or discontinuing the opioid may allow recovery of the axis over time.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total and free testosterone (with LH, FSH)
- Prolactin (opioid-related elevation)
- Morphine-equivalent daily dose review
- Bone density with prolonged hypogonadism
What people get wrong
Often saidLow libido on long-term opioids is just the pain or depression
ActuallyOften it is measurable hormonal suppression. Opioids directly inhibit the GnRH signal, and most studies find more than half of chronic users are hypogonadal.
Often saidTestosterone replacement is the answer for OPIAD
ActuallyIt may relieve symptoms, but the root cause is the opioid. Where clinically possible, reducing the opioid can let testosterone recover on its own.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Prevalence
- ~19-86% across studies; most report >50%
- Onset
- Dose-dependent; can develop within weeks of higher-dose therapy
- Primary mechanism
- Suppression of hypothalamic GnRH (secondary hypogonadism)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Opioid-Induced Hypogonadism (OPIAD). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Kafel et al., Andrology, review of OPIAD prevalence, pathophysiology and testosterone therapy2025
Synthesizes prevalence (most studies >50%), the GnRH-suppression mechanism, and effects on sexual function, mood, bone and body composition
Studies of testosterone deficiency in non-cancer opioid-treated patients2018
Report high rates of hypogonadism and dose-dependence in chronic non-cancer opioid users